| Literature DB >> 34804972 |
Jibo Jing1,2,3, Jin Sun4, Yuqing Wu1,2,3, Nieke Zhang1,2,3, Chunhui Liu1,2,3, Saisai Chen1,2,3, Wenchao Li1,2,3, Cheng Hong1,2,3, Bin Xu1,2,3, Ming Chen1,2,3.
Abstract
BACKGROUND: It is undeniable that the tumor microenvironment (TME) plays an indispensable role in the progression of kidney renal clear cell carcinoma (KIRC). However, the precise mechanism of activities in TME is still unclear. METHODS ANDEntities:
Keywords: AQP9; TCGA; extracellular matrix (ECM); renal clear cell carcinoma (KIRC); tumor microenvironmental; tumor-associated macrophages (TAMs)
Year: 2021 PMID: 34804972 PMCID: PMC8602816 DOI: 10.3389/fonc.2021.770565
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244
Figure 1Flowchart of the research.
Baseline characteristics of enrolled cases.
| Characteristics | TCGA cohort n = 537 No. of patients (%) | ICGC cohort n = 90 No. of patients (%) |
|---|---|---|
| Age ≤65 | 336 (62.57) | 62 (68.89) |
| Male | 346 (64.43) | 51 (56.67) |
| Pathologic_T | ||
| T1 | 275 (51.21) | 54 (60.00) |
| T2 | 69 (12.85) | 13 (14.44) |
| T3 | 182 (33.89) | 21 (23.33) |
| T4 | 11 (2.05) | 2 (2.22) |
| Tx or unknown | 0 | 0 |
| Pathologic_M | ||
| M0 | 426 (79.33) | 81 (90.00) |
| M1 | 79 (14.71) | 8 (8.89) |
| Mx or unknown | 32 (5.96) | 1 (1.11) |
| Pathologic_N | ||
| N0 | 240 (44.69) | 78 (86.67) |
| N1 | 17 (3.17) | 2 (2.22) |
| Unknown | 280 (52.14) | 10 (11.11) |
| Histologic_grade | ||
| G1 | 14 (2.61) | |
| G2 | 230 (42.83) | |
| G3 | 207 (38.55) | |
| G4 | 78 (14.53) | |
| Gx or unknown | 8 (1.49) | |
| Tumor_stage | ||
| Stage I | 269 (50.09) | |
| Stage II | 57 (10.61) | |
| Stage III | 125 (23.28) | |
| Stage IV | 83 (15.46) | |
| Status | ||
| Alive | 360 (67.04) | 61 (67.78) |
| Dead | 177 (32.96) | 29 (32.22) |
| Unknown | 3 (0.56) | 0 |
| Follow-up time | ||
| t ≤365 | 97 (18.06) | 7 (7.78) |
| 1,825 ≥ t > 365 | 290 (54.00) | 42 (46.67) |
| t >1,825 | 150 (27.93) | 41 (45.56) |
ICGC, International Cancer Genome Consortium; TCGA, The Cancer Genome Atlas.
Figure 2ImmuneScore is correlated with survival of kidney renal clear cell carcinoma (KIRC) patients and clinical TNM staging. (A–C) According to the ESTIMATE algorithm, survival analysis of high and low ImmuneScore, StromalScore, and ESTIMATEScore. Panels (D–F) show the bar plot of the three scores with tumor clinical staging and TNM staging, respectively.
Figure 3Enrichment analysis of differentially expressed genes (DEGs). DEGs of two immune-related ingredients in tumor microenvironment (TME) were shown in panels (A, B). In panel (C), a total of 286 genes shared by the ImmuneScore and StromalScore. (D–F) Result of Gene Ontology (GO) enrichment analysis. (G–I) Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis of DEGs.
Figure 4The screening process and initial validation in clinical information of aquaporin 9 (AQP9). Genes with the top 20 Interaction node number (B) according to protein–protein interaction (PPI) network (A) were screened out. (D) Overlap between the uni-Cox regression (C) and PPI network. Expression bar chart (E), paired expression bar chart (F), and survival analysis (G) of AQP9. (H–K) The expression level of AQP9 in kidney renal clear cell carcinoma (KIRC) patients with different clinical and TNM stages.
Figure 5(A) The differential expression of AQP9 in International Cancer Genome Consortium (ICGC) tumors and adjacent tissues. (B) Survival analysis from of data form ICGC cohort. (C, D) Correlation plot of aquaporin 9 (AQP9) to programmed cell death-1 (PD-1) and AQP9 to programmed cell death-ligand 1 (PD-L1). (E) AQP9 predicting immune response by IMvigor210. (F, G) Result of gene set enrichment analysis (GSEA).
Figure 6Relationship between aquaporin 9 (AQP9) and immune cells. (A) The differential expression of various types of immune cells in cancer and adjacent tissues. (B) Overlap of correlation and differential analysis of AQP9. (C–K) Correlation analysis of the expression of AQP9 and the level of different immune cells.
General information of clinical samples.
| Tumor | |||||||
|---|---|---|---|---|---|---|---|
| Patients | Gender | Age | Tumor size (cm) | Location of tumor | Stage | TNM stage | Pathological type |
| Patient 1 | Male | 64 | 4.7 × 4.3 × 4.5 | Left | Stage I | T1aN0M0 | KIRC |
| Patient 2 | Male | 59 | 3.5 × 4.5 × 2.5 | Upper right | T1bNxM0 | KIRC | |
| Patient 3 | Female | 48 | 3.2 × 3.5 × 3.3 | Right | T1aNxMx | KIRC | |
| Patient 4 | Male | 69 | 2 × 2 × 2 | Right | Stage II | T2aN0M0 | KIRC |
| Patient 5 | Female | 47 | 5×4×1.5 | lower left | T2bNxMx | KIRC | |
| Patient 6 | Male | 72 | 7.5×6×6.5 | left | Stage III | T3N1M0 | KIRC |
The clinical features of the six kidney renal clear cell carcinoma (KIRC) patients.
Figure 7Validation in kidney renal clear cell carcinoma (KIRC) patients. (A) The real-time quantitative PCR (RT-qPCR) result of aquaporin 9 (AQP9) in patients of different KIRC stages. (B) Simple linear regression of AQP9 level according to the different stages. (C, D) Multiple immunohistochemistry (mIHC) result of AQP9, CD163, and CD8 in KIRC tumor tissue.